This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 May 10;28(14):e221-2; author reply e223-5.

doi: 10.1200/JCO.2009.27.4928. Epub 2010 Mar 29.

Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing

Elisa Giovannetti, Carmelo Tibaldi, Alfredo Falcone, Romano Danesi, Godefridus J Peters

PMID: 20351322
DOI: 10.1200/JCO.2009.27.4928

Comment

Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing

Elisa Giovannetti et al. J Clin Oncol. 2010.

. 2010 May 10;28(14):e221-2; author reply e223-5.

doi: 10.1200/JCO.2009.27.4928. Epub 2010 Mar 29.

Authors

Elisa Giovannetti, Carmelo Tibaldi, Alfredo Falcone, Romano Danesi, Godefridus J Peters

PMID: 20351322
DOI: 10.1200/JCO.2009.27.4928

No abstract available

PubMed Disclaimer

Comment on

Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C. Ciccolini J, et al. J Clin Oncol. 2010 Jan 1;28(1):160-5. doi: 10.1200/JCO.2009.24.4491. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933910

Similar articles

Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier C, Evrard A, Ciccolini J. Mercier C, et al. J Clin Oncol. 2007 Oct 20;25(30):4855; author reply 4855-6. doi: 10.1200/JCO.2007.13.3918. J Clin Oncol. 2007. PMID: 17947739 No abstract available.
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X, Chen W, Fan H, Zhu B. Ding X, et al. Gene. 2015 Mar 15;559(1):31-7. doi: 10.1016/j.gene.2015.01.010. Epub 2015 Jan 10. Gene. 2015. PMID: 25582275 Review.
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C, Ciccolini J, Mercier C, Boyer JC, Polge A, Lallemant B, Mouzat K, Lumbroso S, Brouillet JP, Evrard A. Raynal C, et al. Ther Drug Monit. 2010 Feb;32(1):53-60. doi: 10.1097/FTD.0b013e3181c77c1b. Ther Drug Monit. 2010. PMID: 20010457
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N. Sugiyama E, et al. J Clin Oncol. 2007 Jan 1;25(1):32-42. doi: 10.1200/JCO.2006.06.7405. J Clin Oncol. 2007. PMID: 17194903
[Prediction of adverse drug reactions based on genomic information].
Sawada J, Saito Y. Sawada J, et al. Nihon Rinsho. 2007 Oct 28;65 Suppl 8:16-21. Nihon Rinsho. 2007. PMID: 18074510 Review. Japanese. No abstract available.

See all similar articles

Cited by

Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J, Mercier C, Dahan L, André N. Ciccolini J, et al. Nat Rev Clin Oncol. 2011 Feb 8;8(7):439-44. doi: 10.1038/nrclinonc.2011.1. Nat Rev Clin Oncol. 2011. PMID: 21304503 Review.
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Emadi A, Karp JE. Emadi A, et al. Pharmacogenomics. 2012 Aug;13(11):1257-69. doi: 10.2217/pgs.12.102. Pharmacogenomics. 2012. PMID: 22920396 Free PMC article. Review.
Pancreatic cancer: why is it so hard to treat?
Oberstein PE, Olive KP. Oberstein PE, et al. Therap Adv Gastroenterol. 2013 Jul;6(4):321-37. doi: 10.1177/1756283X13478680. Therap Adv Gastroenterol. 2013. PMID: 23814611 Free PMC article.
CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R. Fanciullino R, et al. Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126. Blood Adv. 2018. PMID: 29490977 Free PMC article.
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Ciccolini J, et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):1-12. doi: 10.1007/s00280-016-3003-0. Epub 2016 Mar 23. Cancer Chemother Pharmacol. 2016. PMID: 27007129 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.